Treatment Registry
TR-0805 ActiveRecorded September 2, 2026

Compounded tirzepatide

Sold by JRNYS · every compounded tirzepatide record

The register has not established whether this program ships a vial, a pen, or another form. That is a gap in our record, not a statement about the company.

What you actually pay

Per month

$305

Medication · Compounded Tirzepatide Microdose, cash pay, all-inclusive (not the brand-Mounjaro/Zepbound path above)$216
Required membership$89

Added from the figures recorded below.

Price

TermPer monthCharged today
Compounded Tirzepatide Microdose, cash pay, all-inclusive (not the brand-Mounjaro/Zepbound path above)

Physician-Backed Tirzepatide Microdose from $216/m

source

Per month$216Charged today$216
Visit JRNYS

We earn nothing from this link. JRNYS has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.

History

One reading so far. A price history appears here after the next verification pass.

  • September 2, 2026Entry added to the register

Sourcing and terms

PrescriberAsynchronous review
Cancellation“Subscribers are required to give a notice of at least 7 days prior to their next billing cycle for cancellation of their subscription.”
MembershipRequired. $89 per month. “Start for $89/month* *Does not include the cost of medication. ... Membership ranges from $89 per month to $169 per month depending on your level of 1-1 coach support. The base price includes your medical visits, daily monitoring, coaching & access to member exclusive content.”

Not yet checked: pharmacy, states and consult fee.

Recorded from jrnys.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. September 2, 2026Textbook membership trap: the headline '$89/month' figure repeated across the whole site is explicitly footnoted '*Does not include the cost of medication' and confirmed on product pages as a $89-$169/mo membership fee only. JRNYS sells brand-name GLP-1s (Ozempic, Mounjaro, Zepbound, Wegovy) via insurance navigation, for which the only price given is an insurance-capped '$25 per month after any deductible is met' (an insurance price, recorded separately per the brief's rule) — no cash price for the brand path is published. Separately, JRNYS also sells a 'Compounded Tirzepatide Microdose' product at a flat 'from $216/m' cash price, framed as inclusive ('Compounded medications are not FDA-approved... prepared by licensed pharmacies'); this is NOT the same product as the branded Mounjaro/Zepbound path and is recorded as its own entry. Also found a real self-contradiction: the Cancellation Policy page says 'your initial telehealth fee of $89 will not be refunded,' while the Terms & Conditions page says 'your initial telehealth fee of $35 will not be refunded' for the same fee — flagged, not resolved. No page stating served states was found. Footer legal text names a 'KINSYN' brand ('KINSYN provides clinician-guided wellness and metabolic health programs') alongside JRNYS, suggesting a shared backend across brands.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0805
Readings
1

Related records

What else JRNYS sells

  • JRNYS · brand semaglutide$25 at insurance price (most members with commercial insurance, after deductible; excludes the separate $89-$169/mo membership fee — see membership)
  • JRNYS · brand tirzepatide$25 at insurance price (most members with commercial insurance, after deductible; excludes the separate $89-$169/mo membership fee — see membership)

All JRNYS programs and terms

Compounded tirzepatide at a similar price

The records either side of this one in the recorded spread. Not a ranking, and not a recommendation — a position among 307 records of the same molecule.

Cite this entry

Treatment Registry. (2026). JRNYS compounded tirzepatide (TR-0805). Last verified September 2, 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0805

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.